
Resof-l
Salt Composition: Sofosbuvir and Ledipasvir
Expiry Date: 01/2028
Inclusive of all taxes
28 tablet
About The Product
Hepatitis C
Resof-L Tablet is an antiviral medication, which is used in combination with other medicines. It is used in the treatment of chronic hepatitis C virus (HCV) infection. It stops or prevents the growth of viruses in the body and helps remove the virus from the blood. Resof-L Tablet helps you to recover faster and control the infection from spreading in your body. This is a prescription-based medicine, which is to be taken only when prescribed by your doctor.
Uses
Treatment of Chronic hepatitis C virus (HCV) infection
Side Effects
- The human body reacts differently to Resof-L Tablet.
- Response or undesired symptoms vary from individual to individual.
- Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention.
- Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.
- Some of the common side effects of Resof-L Tablet are mentioned below: Headache Fever Chills Nausea Insomnia (difficulty in sleeping)
- Tiredness Loss of appetite Fatigue Anemia (low number of red blood cells)
- Skin rash
How To Use
- Take the dose of Resof-L Tablet as per your healthcare provider’s prescription.
- Do not stop taking the medicine suddenly, unless your doctor tells you.
- This medicine is given under the strict supervision of a doctor.
- Do not self-administer.
- Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider.
- Resof-L Tablet can be taken without food or with food.
- The doctor will provide emergency medical treatment.
- You should not break, crush, or chew the medicine; it should be swallowed as a whole.
- It is advised to eat a healthy diet and drink plenty of fluids to overcome and prevent the side effects that have occurred after taking Resof-L Tablet.
How It Works
Resof-L Tablet is an antiviral medicine made up of Sofosbuvir and Ledipasvir. Both ingredients present in the medicine prevent the virus from multiplying.
Thus, the viral count in the blood gets lowered, and the infection can be eliminated from the body. This medication is suitable for use in both adults and children aged three years and above.
Resof-L Tablet inhibits an important Nonstructural protein 5A (NS5A) and viral phosphoprotein, which are involved in replication of the virus, assembly, secretion, and RNA viral production.
Safety Advice
FAQs
Resof-L Tablet is an antiviral medication, used along with other medications, in the treatment of chronic Hepatitis C Virus (HCV) infection in adults.
Reference
Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. (2023). Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 16(4):459-64.
Duc N. T, Vittorio F, Alexander Z, Venkat R. G, Akihiro H, Mingjun H, Jason A. W. (2025). The Discovery and Chemical Development of Odalasvir, a Potent and Selective HCV NS5A Inhibitor, Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5, 1-58.
Lele Z, Matthew H, Prahalad G, Mahan G, Steven K, Haiting C, Paul K, Eleanor B, M. Azim A, Katrina L, Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure, PLOS Pathogens, 21, 4, (e1012959).
Nambaru Vidya Sagar, Anamika Goyal, Abhishek Raj, Subhash Chandra, Upendra Nath Gupta, Prabhat Agrawal, Rajat Gupta, Rahul Agrahari. (2024). SVR timelines in hepatitis irrespective of viral genotype: An Indian perspective, Journal of Family Medicine and Primary Care, 14, 4, 1425-1430.
Preferred Therapy for Specific Viral Pathogens, Nelson’s Pediatric Antimicrobial Therapy, (2025).
Thomas R. O, David J. W, Varun S, Kerry G.M., Sabrina C, Francine S.B., Ludmila P. O, Ruth M. P, Jennifer B. L. (2024). IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C, Journal of Infection, 89, 5, (106258).
Yong P, Sitthichai K, Nungruthai S, Pornjarim N, Ritthideach Y, Wijittra P, Napaporn P, Chatree J. (2025). Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions, Journal of Clinical Medicine, 14, 11, 3946.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
